Colleen Delaney

Colleen Delaney is the Founder, CSO, and Executive Vice President of Research and Development of Deverra Therapeutics, a cellular therapy company focused on the development of universal donor, off-the-shelf cell therapies for patients with hematologic malignances and other critical diseases. Prior to Deverra, Dr. Delaney was the Scientific Founder and Chief Medical and then Chief Scientific Officer of Nohla Therapeutics, Inc. She is also an Affiliate and former Member of the Fred Hutchinson Cancer Research Center Clinical Research Division where she also held the Madeline Dabney Adams Endowed Chair in AML Research and was the principal investigator of an active, NIH-funded laboratory. In 2006, she established and became the Director of the Cord Blood Transplant Program at the Fred Hutch/Seattle Cancer Care Alliance. She is a Professor at the University of Washington in the Department of Pediatrics, Division of Pediatric Hematology/Oncology.